Zubsolv (buprenorphine naloxone)
Zubsolv® is indicated for substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is indicated in adults and adolescents over 15 years of age who have agreed to be treated for addiction. Link to Abbreviated Prescribing Info available below.
API Documents
Patient Information Leaflets (PILs)
You can report side effects directly via the HPRA website www.hpra.ie, by emailing the HPRA Pharmacovigilance department at [email protected], or by calling the HPRA on 01-676 4971.
Please also report side effects to Accord Healthcare Ireland Ltd, by calling 0044 (0) 1271 385257. By reporting side effects you can help provide more information on the safety of this medicine.
Information placed on this digital platform is not intended as a substitute for consultation with your healthcare professional.
Please consult your healthcare professional for further information.
Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the HPRA website www.hpra.ie, by emailing the HPRA Pharmacovigilance department at [email protected], or by calling the HPRA on 01-676 4971.
Please also report side effects to Accord Healthcare Ireland Ltd, by calling 0044 (0) 1271 385257.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.
By reporting side effects you can help provide more information on the safety of this medicine.
